CB-13 Stats & Data

• Identity warning: “CB‑13” refers to at least two unrelated cannabinoids in the literature. Recreational markets and some lists use “CB‑13” for a naphthoyl–naphthyl ketone, while pharmacology papers use CB‑13 = SAB‑378 (peripherally restricted CB1/CB2 agonist). Verify you have SAB‑378; misidentification increases risk.

• Peripherally restricted does not guarantee zero central effects: very high plasma levels or BBB changes (e.g., illness, co-intoxication) can allow some CNS penetration, so treat impairment as possible at higher doses. This is a general BBB principle for peripherally targeted drugs.

• Cannabinoids can cause tachycardia and lower blood pressure; standing up quickly may cause light-headedness or fainting. Sit/lie down if dizzy; avoid combining with other vasodilators (e.g., poppers, PDE5 inhibitors).

• Avoid driving or hazardous tasks until fully sober and well rested; cannabis-like agents are associated with increased motor vehicle crash risk, especially when combined with alcohol. A conservative minimum of 6–8 h is advisable after oral dosing.

• If acquired as an unlabeled powder, consider laboratory drug checking (GC/MS, LC/MS) to confirm identity/purity. Note some services do not accept cannabis/cannabinoid products, but may analyze powders.

• Smoking/vaping synthetic cannabinoids has historically led to uneven dosing and ‘hot pockets’ in herbal blends; if vaporizing neat material, use the lowest effective temperature and small test puffs to reduce pyrolysis exposure. Avoid homemade sprayed herbal products.

• Start with an allergy test (e.g., ≤25 mg oral or ≤5 mg vapor) due to unknown excipients and the absence of formal human safety data; increase in small steps with long waits (≥2–3 h oral; ≥45–60 min inhaled) before redosing. Rationale: unregulated supply variability and cannabinoid interindividual sensitivity.

• Combining with CNS depressants (alcohol, opioids, benzodiazepines, sedating antihistamines) markedly increases sedation and accident risk; with opioids and/or gabapentinoids the risk of respiratory depression is higher than either alone.

• Expected effects are mostly peripheral (analgesia, anti-inflammatory, body relaxation, mild warmth) with relatively muted classic cannabis ‘high’; users often report sedation and dry mouth, and at higher doses nausea or orthostatic symptoms.

• Legal and market shifts can lead to mislabeling with other potent synthetic or semi-synthetic cannabinoids; variable potency between batches is well-documented. Test a new batch cautiously.